On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.

The move was driven by a broad rally across the Life Sciences Tools and Services sector, with WUXI XDC up 10.02%, PHARMARON up 9.22%, WUXI BIO up 6.81%, GENSCRIPT BIO up 5.86%, and WUXI APPTEC up 5.73%. On the company level, multiple recent catalysts provided support: the NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biosciences, received NMPA clinical trial approval for Parkinson's disease treatment. The drug features blood-brain barrier penetration capability, differentiating it from peripherally-restricted competitors. Additionally, JPMorgan initiated coverage with an Overweight rating and a HK$71 target price, providing further valuation support alongside the sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)